Arcellx, INC Schedule 13D activist filings

New Enterprise Associates has ceased to be a beneficial owner of Arcellx, Inc. following the completion of the company's acquisition by Gilead Sciences.

Arcellx, Inc. has been acquired by Gilead Sciences, Inc. through a tender offer and subsequent merger, with shareholders receiving $115 per share plus a contingent value right.

Gilead Sciences has finalized its acquisition of Arcellx, Inc. following a successful tender offer and subsequent merger, making Arcellx a wholly owned subsidiary.

New Enterprise Associates and other major stockholders agree to tender shares in Arcellx's acquisition by Gilead Sciences for $115 cash and a $5 CVR per share.

Arcellx, Inc. shareholders to receive $115 cash plus a $5 CVR per share in Gilead Sciences acquisition.

Gilead Sciences, Inc. announced a definitive agreement to acquire Arcellx, Inc. for approximately $7.8 billion in cash and contingent value rights.

New Enterprise Associates (NEA) updated its beneficial ownership in Arcellx, Inc., reflecting pro rata share distributions to its partners and subsequent individual sales.

New Enterprise Associates (NEA) has filed an Amendment No. 3 to its Schedule 13D for Arcellx, Inc., disclosing a decrease in its beneficial ownership percentage to 6.8% due to an increase in Arcellx's outstanding common stock.

Rami Elghandour, a key executive at Arcellx, Inc., has updated his beneficial ownership stake to 6.9% following the partial vesting of performance-based equity awards and subsequent sales to cover tax obligations.